Home › Funds › Logos Global Management LP › DYN

Logos Global Management LP position in DYN

DYNE THERAPEUTICS INC · Health Care

Logos Global Management LP reported holding 2,550,000 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$56.6M, representing 2.44% of its reported portfolio and ranking #14 among its reported holdings. Logos Global Management LP has disclosed DYN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.55M sh
Reported value held$56.64M
Portfolio Weight2.44%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Logos Global Management LP's DYN position evolved

Logos Global Management LP first disclosed a stake in DYN in Q3 2023 at 2,180,000 shares (US$19.5M). The position peaked in Q2 2026 at 2,550,000 shares, worth US$56.6M. Across 12 filings, Logos Global Management LP increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,550,000 shares valued at US$56.6M — an increase of 1,150,000 shares quarter over quarter.. Notable position changes include a 85% trim in Q2 2024 (shares rose 2% over the following quarter), a 181% increase in Q4 2024 (shares fell 56% over the following quarter), a 280% increase in Q2 2025 (shares rose 33% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.18M $19.53M New
Q4 2023 1.88M $25.00M Reduce
Q1 2024 1.73M $49.11M Reduce
Q2 2024 265.00K $9.35M Reduce
Q3 2024 160.00K $5.75M Reduce
Q4 2024 450.00K $10.60M Add
Q1 2025 500.00K $5.23M Add
Q2 2025 1.90M $18.09M Add
Q3 2025 2.40M $30.36M Add
Q4 2025 1.25M $24.45M Reduce
Q1 2026 1.40M $25.38M Add
Q2 2026 2.55M $56.64M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has Logos Global Management LP held DYN?

Logos Global Management LP has disclosed DYN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Logos Global Management LP's current position in DYN?

As of Q2 2026, Logos Global Management LP holds 2.55M shares of DYN (DYNE THERAPEUTICS INC), valued at $56.64M, representing 2.44% of its reported portfolio and ranking #14.

Has Logos Global Management LP been buying or selling DYN?

In the latest 13F filing (Q2 2026), Logos Global Management LP increased its position in DYN. The position peaked in Q2 2026 at 2.55M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.